Madrigal Pharmaceuticals, Inc. (MDGL) Upgraded to Outperform at Wolfe Research

Market Context

Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $507.56 with a market capitalization of $12.7B. The stock has gained 49.8% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Wolfe Research's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Madrigal Pharmaceuticals, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 04, 2026	Wolfe Research	Outperform	N/A
Aug 03, 2026	Barclays	Overweight	N/A
Jul 29, 2026	Canaccord Genuity	Buy	N/A
Jul 27, 2026	Wells Fargo	Overweight	N/A
Jun 11, 2026	B of A Securities	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View MDGL Stock Page